Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 20/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 20/20 | 0.46 |
| ▸ | TSPO | P30536 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3413929 | 1.00 | HCRTR1 (0.46) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL3413926 | 1.00 | HCRTR1 (0.46) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL3412050 | 1.00 | HCRTR1 (0.46) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL3415370 | 0.92 | HCRTR1 (0.45) | HCRTR1HCRTR2 | |
| SCHEMBL2928163 | 0.90 | HCRTR1 (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL3417963 | 0.90 | HCRTR1 (0.55) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL2924769 | 0.90 | HCRTR1 (0.55) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL2929909 | 0.88 | HCRTR1 (0.48) | HCRTR1HCRTR2 | |
| SCHEMBL3418137 | 0.88 | HCRTR1 (0.40) | HCRTR1HCRTR2 | |
| SCHEMBL3413154 | 0.88 | HCRTR1 (0.49) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079690-B1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-15 | — | — | EP | claimed |
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | Actelion Phamaceuticals Ltd. (CH) | 2010-01-21 | — | — | US | claimed |
| EP-2079690-B1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | Actelion Phamaceuticals Ltd. (CH) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | HCRTR1, HCRTR2, CNR1 | HCRTR1 1/4885HCRTR2 2/4885TSPO 1712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.